%0 Journal Article
%T Peptide receptor radionuclide therapy with lutetium-177 DOTATATE in a case of recurrent extradrenal retroperitoneal malignant paraganglioma with nodal and bone metastasis
%A Koramadai Kamaleshwaran
%A Paulvannan Subramaniam
%A Sudhakar Natarajan
%A Pavanasam Velayutham
%A Vyshak Mohanan
%A Ajit Shinto
%J Clinical Cancer Investigation Journal
%@ 2278-0513
%D 2015
%V 4
%N 1
%R 10.4103/2278-0513.149058
%P 84-87
%X Extra-adrenal retroperitoneal paragangliomas (PGLs) are rare tumors causing considerable difficulty in both, diagnosis and treatment. They can be unicentric or multicentric, tend to be locally invasive and therefore have a high incidence of local recurrence. PGLs shows somatostatin receptor positivity, which can be imaged with technetium-99m (Tc-99m)-hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) and can be treated with lutetium-177 (Lu-177) DOTATATE. We present a case of recurrent unresectable retroperitoneal PGL with nodal and bone metastases in a 27-year-old male, 6 months postsurgery detected with Tc-99m-HYNIC-TOC and was administered with peptide receptor radionuclide therapy using Lu-177 DOTATATE.
%U https://ccij-online.org/article/peptide-receptor-radionuclide-therapy-with-lutetium-177-dotatate-in-a-case-of-recurrent-extradrenal-retroperitoneal-malignant-paraganglioma-with-nodal-and-bone-metastasis-328